Rubenstein Public Relations Named Agency of Record for OS Therapies
Globe Newswire (Thu, 8-Oct 9:22 AM ET)
TipRanks (Wed, 7-Oct 12:35 PM ET)
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
Newsfile (Wed, 7-Oct 8:32 AM ET)
OS Therapies Incorporated (OSTX) Receives a Buy from Roth MKM
TipRanks (Tue, 6-Oct 12:35 PM ET)
Market Chameleon (Tue, 6-Oct 6:28 AM ET)
Newsfile (Tue, 6-Oct 8:30 AM ET)
Newsfile (Thu, 1-Oct 8:30 AM ET)
Newsfile (Thu, 24-Sep 8:24 AM ET)
Newsfile (Mon, 21-Sep 6:30 AM ET)
OSTX Gains FDA Alignment on Phase 3 Adaptive Design as MHRA Leads Project Orbis for OST-HER2
Market Chameleon (Thu, 17-Sep 6:26 AM ET)
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
Os Therapies trades on the AMEX stock market under the symbol OSTX.
As of October 9, 2026, OSTX stock price was flat at $1.62 with 407,983 million shares trading.
OSTX has a beta of 1.41, meaning it tends to be more sensitive to market movements. OSTX has a correlation of 0.07 to the broad based SPY ETF.
OSTX has a market cap of $75.82 million. This is considered a Micro Cap stock.
Last quarter Os Therapies reported $0 in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-204,400 and exceeded earnings estimates by $.03.
The top ETF exchange traded funds that OSTX belongs to (by Net Assets): VTI, VXF, IWC, BUSM.
OSTX has underperformed the market in the last year with a price return of -20.6% while the SPY ETF gained +17.1%. OSTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.8% and -2.4%, respectively, while the SPY returned +3.8% and +0.9%, respectively.
OSTX support price is $1.54 and resistance is $1.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OSTX shares will trade within this expected range on the day.
